VEGFA and neoplasm: We next evaluated the effect of bevacizumab on endogenous levels of tumor-derived sEV-VEGF and non-sEV-VEGF by treating mice bearing subcutaneous (s.c.)tumors derived from parental ES2 and HCT116 cells with bevacizumab for 1 week.